Amneal·Zambon Hopledo Approved in EU as Parkinson's Disease Treatment
EU Approval Extends U.S. Commercial Success to Europe
The European Union approved Hopledo (levodopa/carbidopa) for sale on August 20, 2026. The approval is for adult patients with moderate to severe motor fluctuations who are not adequately stabilized with oral levodopa plus COMT inhibitor therapy, and the development stage is approved and commercial. Levodopa is a dopamine precursor, and carbidopa inhibits peripheral aromatic L-amino acid decarboxylase (AADC), increasing the amount of levodopa reaching the brain. In the U.S., the same formulation was approved by the FDA on August 7, 2024, under the brand name Crexont and launched in September 2024.
RISE-PD Demonstrated Reduced Dosing Frequency and Symptom Control
The Phase 3 RISE-PD (NCT03670953), which served as the basis for approval, was a 20-week study randomizing 506 patients with motor fluctuations to compare Hopledo with immediate-release levodopa/carbidopa. Hopledo, administered three times daily, extended Good ON-time without troublesome dyskinesia by 0.53 hours compared to the five-dose control group, with a 95% confidence interval of 0.09–0.97 hours and a p-value of 0.02. ON-time per dose increased to 3.76 hours from 2.21 hours, a 1.55-hour improvement. Common adverse reactions included nausea at 4.3% and anxiety at 2.7%. The EMA noted that while the efficacy improvement was modest, the reduced dosing frequency could lower treatment burden for elderly patients.
Competitive Focus Lies in Levodopa Delivery and OFF-Time Management
Standard treatments include Sinemet (levodopa/carbidopa) immediate- and extended-release, Stalevo (levodopa/carbidopa/entacapone), and Duodopa (levodopa/carbidopa) administered via intestinal infusion. Dopamine agonists like ropinirole and pramipexole, as well as Xadago (safinamide; MAO-B inhibitor) and Ongentys (opicapone; COMT inhibitor), are also used in combination to reduce OFF episodes. Hopledo differentiates itself with stable levodopa exposure and lower dosing frequency in the pre-pump therapy phase, although the mean daily pill count in the trial was 10.6, higher than the control group's 8.7. The European Parkinson's disease treatment market was valued at $1.5652 billion in 2024, so actual competitiveness will depend on country-specific pricing, reimbursement, and patient conversion rates.
Zambon's Neurology Sales Network and Amneal's Manufacturing Capabilities Combine
Amneal Pharmaceuticals, Inc. (AMRX) granted Zambon Biotech SA exclusive development and commercialization rights in the EU, UK, and Switzerland in February 2024, and Zambon plans to launch the product sequentially in Europe starting October 2026. The agreement period is 15 years post-commercial launch, with Zambon handling regulatory and commercialization and Amneal responsible for post-approval manufacturing and supply. Amneal received a $5 million non-refundable upfront license payment and secured up to $71.5 million in regulatory, launch, and annual net sales milestones, as well as single-digit to low double-digit royalty rates tied to net sales. Given that a $1.5 million regulatory milestone was paid by September 2024, EU approval and launch are structured to trigger subsequent cash inflows.
EU approval transforms Hopledo from a Phase 3 asset into a commercial product in the $1.5652 billion European Parkinson's disease treatment market in 2024. While the RISE-PD study improved ON-time by 0.53 hours, it reduced daily dosing from five to three times, providing a differentiation basis against Sinemet and Stalevo. For researchers, the 1.55-hour extension in ON-time per dose is a key validation metric for extended-release delivery technology, and adverse reaction management in patients over 75 and those with renal impairment remains a post-marketing research priority. For the industry, the 15-year licensing model combining Zambon's Xadago sales network and Amneal's manufacturing and supply capabilities exemplifies a cost-effective European market entry strategy. Short-term value hinges on sequential launches starting October 2026 and reimbursement inclusion, while mid-to-long-term value depends on the speed of achieving up to $71.5 million in milestones and realizing single-digit to low double-digit royalty rates.
Source: EMA (ema)